Introduction {#s1}
============

Thoracotomy, the surgical incision of the pleural cavity or chest wall, induces severe postoperative pain [@pone.0096233-Kavanagh1]. The pain can cause respiratory complications such as hypoxia (inadequate oxygen), atelectasis (lung collapse) and pulmonary infection due to shallow breathing and impaired coughing. If severe enough, the postoperative pain can lead to dreadful respiratory disorders including respiratory failure and other complications [@pone.0096233-Sabanathan1].

In addition, chronic pain after thoracotomy is common and may continue for many years, especially in patients who experienced acute post-operative pain [@pone.0096233-Plumis1], [@pone.0096233-Soto1]. However, adequate postoperative analgesia facilitates recovery [@pone.0096233-Joshi1].

Regional anesthesia may reduce the rate of chronic pain after surgery [@pone.0096233-Andreae1]. Although epidural analgesia is clearly effective for managing postoperative pain after thoracotomy, it still has limitations and contraindications. For instance, the number of patients using antiplatelet agents such as aspirin and clopidogrel are considerably more than before. The failure rate of epidural analgesia has been reported to be as high as 12% [@pone.0096233-Hansdottir1]. Epidural analgesia also carries the risk for severe complications such as epidural abscess and spinal hematoma [@pone.0096233-Hansdottir1]. Paravertebral analgesia has been studied as a possible alternative to epidural analgesia for thoracotomy. Because the analgesic effects of paravertebral blockade (PVB) are comparable to epidural analgesia (EPI), PVB may avoid the risks of EPI such as hypotension and urinary retention [@pone.0096233-Horlocker1], and catheterization for PVB can be placed under direct vision during the surgery.

Davies et al. [@pone.0096233-Davis1] reported a systematic review and meta-analysis of 10 randomized trials comparing PVB with EPI. They found that PVB and epidural analgesia provide comparable pain relief after thoracotomy, but PVB had a better side-effect profile and fewer pulmonary complications. However, recent various trials have achieved different results [@pone.0096233-Hotta1]--[@pone.0096233-Kanazi1]. The current study is an updated meta-analysis comparing the efficacy and adverse effects of PVB and EPI in preventing pain associated with thoracotomy.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We identified randomized controlled trials by electronically searching the databases: Pubmed, EMBASE, and the Cochrane Library for reports published from 1 January 2006 to 2 February 2013. The following medical subject headings were included: paravertebral, epidural, thoracotomy, and randomized controlled trial. Alternative spellings were considered when searching. We removed duplicates that were identified in multiple database searches.

Inclusion criteria {#s2b}
------------------

Randomized controlled trials that compared the analgesic efficacy and side effects of PVB and EPI for thoracotomy were included. Studies published only in English were included. The dosages and other details of anesthesia drug administration were not limited. Only studies concerning thoracotomy were allowed and trials regarding breast cancer, and lumbar epidural block were excluded.

Selection of studies {#s2c}
--------------------

Two reviewers (Xibing Ding, Shuqing Jin) used the pre-specified criteria to screen for relevant titles, abstracts, and full papers. An article was removed if it did not meet the inclusion criteria. If these reviewers reached different final selection decisions, a third reviewer (Quan Li, Shukun Fu) was consulted.

Date extraction {#s2d}
---------------

We extracted the following data from the included articles: First author; publishing date; number of patients; study design; description of interventions between PVB and EPI group; postoperative visual analogue scale (VAS) scores at 4--8, 24, and 48 h; morphine usage during the first 24 h; and pulmonary complications, urinary retention, nausea and vomiting, hypotension and failed rate of block. The definitions of the above indicators conformed to those of the original authors. As the primary outcomes, we defined the analgesic effect in terms of VAS scores at postoperative 4--8 h, 24 h, 48 h, and morphine usage during the first 24 h. Secondary outcomes were the remaining pulmonary complications and urinary retention. These data were then compiled into a standard table. The two reviewers (Xibing Ding, Shuqing Jin) who selected the appropriate studies also extracted the data and evaluated the risk of bias. An arbiter (Quan Li) was consulted to reconcile any disagreement.

Assessing the risk of bias {#s2e}
--------------------------

We used the Cochrane Handbook V5.0.2 [@pone.0096233-Higgins1] to assess the risk of bias for all articles. The following information was evaluated: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other bias. Two reviewers (Xiaoyin Niu, Hao Ren) evaluated the methodological quality of all articles. An arbiter (Quan Li) was consulted to reconcile any disagreements.

Statistical analysis {#s2f}
--------------------

Review Manager Software (Revman 5.0, Cochrane Collaboration, Oxford, United Kingdom) was used for the meta-analysis. Heterogeneity among the studies was evaluated using the I^2^ statistic and chi-squared test. A fixed effects model was used if the heterogeneity test did not reveal a statistical significance (I^2^\<50%, *p*\>0.1). Otherwise, we adopted the random effects model. For the continuous variables in the studies included in this meta-analysis (VAS score at postoperative 4--8, 24 and 48 h, and morphine usage at 24 h), used mean difference (MD) and 95% confidence interval (95% CI). For dichotomous variables (pulmonary complications, urinary retention, nausea and vomiting, hypotension, and failed rates of blockage), we used the odds ratio (OR) and 95% CI. All tests of statistical significance were two-sided [@pone.0096233-Egger1]. If the heterogeneity was\>50%, we performed a sensitivity analysis by sequentially removing each study and reanalyzing the remaining dataset. Also, we analyzed only data that had a low risk of bias.

Results {#s3}
=======

Search results {#s3a}
--------------

Initially, 1330 records were identified through the PubMed, EMBASE, and Cochrane Library database ([Fig. 1](#pone-0096233-g001){ref-type="fig"}). Of these, 22 potentially eligible articles, only 9 were found to fulfill the inclusion criteria [@pone.0096233-Hotta1]--[@pone.0096233-Kanazi1]. The remaining 13 article [@pone.0096233-Kaya1]--[@pone.0096233-Ryu1] were removed because the trials did not compare PVB and EPI, or the original data were not available from the authors, or the original data was not relevant to the aims of our study. We just included 9 articles from Davies et al. [@pone.0096233-Davis1], because the results of Wedad et al. included in Davies et al. meta-analysis had no effect on the updated research. Therefore, 18 studies [@pone.0096233-Hotta1]--[@pone.0096233-Kanazi1], [@pone.0096233-Kaiser1]--[@pone.0096233-Bimston1] comprising 777 patients were included in the present meta-analysis ([Table 1](#pone-0096233-t001){ref-type="table"}). A detailed explanation of the full electronic search strategy for Pubmed is shown in [Figure 1](#pone-0096233-g001){ref-type="fig"}. A detailed explanation of the search strategy for the Cochrane Library is shown in [Appendix S1](#pone.0096233.s020){ref-type="supplementary-material"}.

![Flow chart of study selection.](pone.0096233.g001){#pone-0096233-g001}

10.1371/journal.pone.0096233.t001

###### Characteristics of included studies.

![](pone.0096233.t001){#pone-0096233-t001-1}

  Article                  Type of surgery   Number of patients                                                                                     PVB Group                                                                                                                                                                         EPI Group
  ----------------------- ----------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kunihisa et al 2011        Thoracotomy             48           5 ml of 0.75% ropivacaine a bolus dose followed by a 2nd bolus of 5 ml of 0.75% ropivacaine. Then continuous infusion of 0.2% ropivacaine at 4 ml/h over a period of 60 hours.   A continuous infusion of 0.2% ropivacaine at 4 ml/h was started at the end of surgery after the injection of a 2nd bolus of 5 ml of 0.75% ropivacaine and continued for 60 hours
  Jay S et al 2012           Thoracotomy             75                                                                                    0.25% bupivacaine at 8 ml/h.                                                                                  Basal 2 ml/h with 1 ml every 10 minutes via patient-controlled analgesia \[PCA\] were 0.25% bupivacaine alone or 0.25% bupivacaine with 0.01 mg/ml of hydromorphone,
  A Casati et al 2006        Thoracotomy             42                                         15 ml of 0.75% ropivacaine divided into three injections at the T4, T5 and T6 levels (5 ml at each injection site)                                                                                                            5 ml of 0.75% ropivacaine
  Mehta et al 2008           Thoracotomy             36                                                 Bolus dose of 8 ml of 0.5% bupivacaine; infusion of 0.25% bupivacaine at the rate of 0.1 ml/kg/hr                                                                                Bolus dose of 8 ml of 0.5% bupivacaine; an infusion of 0.25% bupivacaine at the rate of 0.1 ml/kg/hr
  Gultekin et al 2009        Thoracotomy             44                            Infusion of 0.25% of bupivacaine at a rate of 0.10 ml/kg/1 h (1 h lock and 2 ml bolus) through patient-controlled elastomeric infusion pump                                         Bupivacaine (5 ml of 0.25%) at a rate of 0.10 ml/kg/1 h (1 h lock and 2 ml bolus) through a patient-controlled elastomeric infusion pump
  Messinaa et al 2009        Thoracotomy             24                           Infusion of 0.25% of bupivacaine at a rate of 0.10 ml/kg 1 h/1 (1 h lock and 2 ml bolus) through patient-controlled elastomeric infusion pump                                      Infusion of 0.25% of bupivacaine at a rate of 0.10 ml kg 1 h 1(1 h lock and 2 ml bolus) through patient-controlled elastomeric infusion pump
  Tatjana et al 2011         Thoracotomy             32                                                                     Combination of 0.5% levobupivacaine and 30 Kg/kg morphine.                                                                                                                        A mixture of 0.25% levobupivacaine with 30 Kg/kg morphine
  Medha et al 2009           Thoracotomy             30                  A bolus dose of bupivacaine 0.5% in a volume of 0.3 ml/kg (1.5 mg/kg) and a continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/hr to 0.2 ml/kg/hr.                      Bupivacaine 0.5% in a volume of 1 mL/segment to 1.5 ml/segment as bolus,then an infusion of bupivacaine 0.125% at a rate of 0.1 ml/kg/hr to 0.2 ml/kg/hr.
  Ghassan et al 2012         Thoracotomy             42                              A loading dose of 20 ml of 0.25% bupivacaine with 5 mg ml 1 of adrenaline,continuous infusion of 0.125% bupivacaine 8 ml/h/1 was started                                                        10 ml of 0.125% bupivacaine wit 5 mg/ml of adrenaline, a continuous infusion of 0.125% bupivacaine 8 ml/h 1
  Kaiser et al 1998          Thoracotomy            124                                        Pre-induction bupivacaine 0.24 bolus; intraoperative bupivacaine 0/5% bolus; postoprative bupivacaine 0.25% infusion                                                                                                      Bupivacaine 0.125%+morphine infusion
  Richardson et al 1999      Thoracotomy             29                                                                                  0.5% bupivacaine bolus infusion                                                                                                                                  Thoracic bupivacaine 0.5% bolus, then bupivacaine 0.125% infusion
  Leaver et al 2006          Thoracotomy             50                                                                                      Ropivacaine 0.475% bolus                                                                                                                                          Thoracic ropvacaine 0.2%+sufentanil bolus, then infusion
  Matthews et al 1989        Thoracotomy             20                                                                                  Bupivacaine 0.25% bolus+infusion                                                                                                                                          Thoracic bupivacaine 0.25% bolus, then infusion
  De Cosmo et al 2002        Thoracotomy             20                                       Pre-induction bupivacaine 0.5% bolus; intraoperative bupivacaine 0.25% bolus; postoperative bupivacaine 0.5% infusion                                                                                                Thoracic bupivacaine 0.25% bolus, then infusion
  Perttunen et al 1995       Thoracotomy             40                                                                                  Bupivacaine 0.25% bolus+infusion                                                                                                                                          Thoracic bupivacaine 0.26% bolus, then infusion
  Dhole et al 2001           Thoracotomy             30                                                                                  Bupivacaine 0.5% bolus+infusion                                                                                                                     Thoracic bupivacaine 0.5% intraoperatively, then 0.25--0.375% bupivacaine+fentanyl infusion
  Luketich et al 2005        Thoracotomy             41                                                                         Bupivacaine 0.5% bolus+bupivacaine 0.25% infusion                                                                                                                          Thoracic bupivacaine 0.5% bolus, then bupivacaine 0.25% infusion
  Bimston et al 1999         Thoracotomy             50                                                                         Bupivacaine 0.5% bolus+bupivacaine 0.25% infusion                                                                                                                          Thoracic bupivacaine 0.5% bolus, then bupivacaine 0.25% infusion

Among the 18 included studies, the insertion methods for PVB varied. PVB was inserted before the surgery in some studies [@pone.0096233-Kaiser1], [@pone.0096233-DeCosmo1] whether the catheter was inserted at the end of surgery in others. Furthermore, the kinds and concentrations of anesthesia drugs are also different. The different concentrations of local anesthetic (LA) were determined by standard for epidural (low LA concentration) and for paravertebral (high LA concentration) analgesia.

Risk of bias of included studies {#s3b}
--------------------------------

According to the Cochrane Handbook V5.0.2, each study had a high risk of bias ([Table 2](#pone-0096233-t002){ref-type="table"}). Thus, the evidence of this meta-analysis has a high overall risk of bias. The authors of each study described it as randomized, but the randomization method was not specified in 8 studies. Six studies used the allocation concealment method. The participants of the allocated treatment could not be blinded because the blockade technique used for each was clinically evident, but those who adjudged outcomes were blinded in three trials. Incomplete outcome data were considered low risk of bias in all articles. Selecting reporting bias was considered 'low' for with no access to each trial\'s original protocol. Among random sequence generation, allocation concealment and blinding, only when any two of them are 'low', the overall risk of bias is considered as low.

10.1371/journal.pone.0096233.t002

###### Risk of bias assessment of included studies.

![](pone.0096233.t002){#pone-0096233-t002-2}

  Article                  overall risk of bias   Random sequence generation   Allocation concealment   Blinding   Incomplete outcome data   Selective reporting   other bias
  ----------------------- ---------------------- ---------------------------- ------------------------ ---------- ------------------------- --------------------- ------------
  Kunihisa et al 2011              High                      Low                      unclear             high               low                     low              high
  Jay S et al 2012                 Low                       Low                        low               low                low                     low              high
  A Casati et al 2006              Low                       Low                        low               low                low                     low              high
  Mehta et al 2008                 high                    unclear                    unclear             high               low                     low              high
  Gultekin et al 2009              low                       Low                        low               high               low                     low              high
  Messinaa et al 2009              low                       Low                        low               high               low                     low              high
  Tatjana et al 2011               low                       low                        low               high               low                     low              high
  Medha et al 2009                 low                       Low                        low               high               low                     low              high
  Ghassan et al 2012               low                       Low                      unclear             low                low                     low              high
  Kaiser et al 1998                high                    unclear                    unclear             high               low                     low              high
  Richardson et al 1999            high                      Low                      unclear             high               low                     low              high
  Leaver et al.2006                high                    unclear                    unclear             high               low                     low              high
  Matthews et al 1989              high                    unclear                    unclear             high               low                     low              high
  De Cosmo et al 2002              high                      Low                      unclear             high               low                     low              high
  Perttunen et al 1995             high                    unclear                    unclear             high               low                     low              high
  Dhole et al 2001                 high                    unclear                    unclear             high               low                     low              high
  Luketich et al 2005              high                    unclear                    unclear             high               low                     low              high
  Bimston et al 1999               high                    unclear                    unclear             high               low                     low              high

Sensitivity analysis {#s3c}
--------------------

We performed a sensitivity analysis of VAS scores at postoperative 4--8 and 24 h. We found that only when Bimston et al. [@pone.0096233-Bimston1] was excluded could heterogeneity be resolved at VAS 4--8 h, but the results did not change \[MD 0.20; 95% CI:0.27 to 0.67; I^2^ = 46%; *p* = 0.05\]. The exclusion of Bimston et al. [@pone.0096233-Bimston1] or Richardson et al. [@pone.0096233-Richardson1] resolved the heterogeneity of VAS scores at 24 h, but this also did not change the results. When we analyzed only data from studies with low risk of bias, we found no heterogeneity = 0%, but there was still no change in results.

The primary outcomes: PVB versus EPI on the analgesic efficacy {#s3d}
--------------------------------------------------------------

The trials assessed pain intensity using the VAS. There was no statistically significant difference in pain scores between the PVB and EPI groups at postoperative 4--8 h (MD 0.36; 95%CI: −0.18 to 0.89; I^2^ = 68%; *p* = 0.19; [Fig. 2A](#pone-0096233-g002){ref-type="fig"}), at 24 h (MD 0.06; 95%CI: −0.31 to 0.42; I^2^ = 54%; *p* = 0.77; [Fig. 2B](#pone-0096233-g002){ref-type="fig"}), or at 48 h (MD −0.13; 95%CI: −0.32 to 0.06; I^2^ = 0%; *p* = 0.19; [Fig. 2C](#pone-0096233-g002){ref-type="fig"}). There was also no significant difference in morphine consumption between the two groups at postoperative 24 h (MD 1.11; 95%CI: −2.20 to 4.41; I^2^ = 0%; *p* = 0.51; [Fig. 2D](#pone-0096233-g002){ref-type="fig"}).

![Meta-analyses of postoperative analgesic efficacy of PVB compared with that of EPI A) VAS scores 4--8 h; B) VAS scores 24 h; C) VAS scores 48 h; D) morphine consumption 24 h.](pone.0096233.g002){#pone-0096233-g002}

Comparison of adverse side effects {#s3e}
----------------------------------

The analyzed adverse side effects consisted of pulmonary complication, urinary retention, nausea and vomiting, hypotension, and failed rates of technique ([Table 3](#pone-0096233-t003){ref-type="table"}). Compared to EPI, PVB resulted in significantly less incidence rates of urinary retention (OR 0.21, 95%CI: 0.10 to 0.44; I^2^ = 0%; *p*\<0.0001; [Fig. 3A](#pone-0096233-g003){ref-type="fig"}), nausea and vomiting (OR 0.49, 95% CI: 0.28 to 0.87; I^2^ = 27%, *p* = 0.01; [Fig. 3B](#pone-0096233-g003){ref-type="fig"}), and hypotension (OR 0.11, 95% CI: 0.05 to 0.25; I^2^ = 0%, *p*\<0.00001; [Fig. 3C](#pone-0096233-g003){ref-type="fig"}). Rates of failed technique were lower in the PVB group (OR 0.51, 95%CI: 0.30 to 0.86; I^2^ = 29%; *p* = 0.01; [Fig. 3D](#pone-0096233-g003){ref-type="fig"}). However, there was no significant difference in pulmonary complications (OR 0.51, 95% CI: 0.23 to 1.11); I^2^ = 0%; *p* = 0.09; [Fig. 3E](#pone-0096233-g003){ref-type="fig"}).

![Meta-analyses of adverse side effect of PVB with that of EPI A) Urinary retention; B) nausea and vomiting; C) hypotension; D) rates of failed technique; E) pulmonary complications.](pone.0096233.g003){#pone-0096233-g003}

10.1371/journal.pone.0096233.t003

###### All detailed results.

![](pone.0096233.t003){#pone-0096233-t003-3}

                                                  Heterogeneity   Test for overall effect   MD/OR    95% CI     Egger\'s Test                        
  -------------------- ------------------------- --------------- ------------------------- ------- ----------- --------------- ------------- ------- --------------
  Primary outcomes            VAS 4--8 h               68                 0.0004            1.30      0.19          0.36        −0.18, 0.89   0.779   −4.81, 6.21
                               VAS 24 h                54                  0.01             0.30      0.77          0.06        −0.31, 0.42   0.923   −3.50, 3.83
                               VAS 48 h                 0                  0.67             1.31      0.19          −0.13       −0.32, 0.06   0.218   −3.50, −0.90
                          morphine usage 24 h           0                  0.55             0.66      0.51          1.11        −2.20, 4.41   0.425   −2.88, 5.58
  Secondary outcomes       Urinary retention            0                  0.43             4.05    \<0.0001        0.21        0.10, 0.44    0.007   −2.59, −0.77
                          Nausea and Vomiting          27                  0.22             2.46      0.01          0.49        0.28, 0.87    0.027   −3.50, −0.32
                              Hypotension               0                  0.98             5.37    \<0.00001       0.11        0.05, 0.25    0.220   −1.91, 0.51
                             Failed block              29                  0.15             2.55      0.01          0.51        0.30, 0.86    0.448   −2.33, 1.18
                        Pulmonary complications         0                  0.47             1.69      0.09          0.51        0.23, 1.11    0.498   −6.11, 3.52

Publication bias {#s3f}
----------------

Visual inspection of the funnel plot and Egger\'s test for publication bias ([Figure S1](#pone.0096233.s001){ref-type="supplementary-material"}, [S2](#pone.0096233.s002){ref-type="supplementary-material"}, [S3](#pone.0096233.s003){ref-type="supplementary-material"}, [S4](#pone.0096233.s004){ref-type="supplementary-material"}, [S5](#pone.0096233.s005){ref-type="supplementary-material"}, [S6](#pone.0096233.s006){ref-type="supplementary-material"}, [S7](#pone.0096233.s007){ref-type="supplementary-material"}, [S8](#pone.0096233.s008){ref-type="supplementary-material"}, [S9](#pone.0096233.s009){ref-type="supplementary-material"}, [S10](#pone.0096233.s010){ref-type="supplementary-material"}, [S11](#pone.0096233.s011){ref-type="supplementary-material"}, [S12](#pone.0096233.s012){ref-type="supplementary-material"}, [S13](#pone.0096233.s013){ref-type="supplementary-material"}, [S14](#pone.0096233.s014){ref-type="supplementary-material"}, [S15](#pone.0096233.s015){ref-type="supplementary-material"}, [S16](#pone.0096233.s016){ref-type="supplementary-material"}, [S17](#pone.0096233.s017){ref-type="supplementary-material"}, [S18](#pone.0096233.s018){ref-type="supplementary-material"}) suggests that there was no evidence of publication bias in VAS scores at postoperative 4--8 h (*p* = 0.779, 95% CI: −4.81 to 6.21), 24 h (*p* = 0.923, 95%CI: −3.5 to 3.83), 48 h (*p* = 0.218, 95% CI: −3.50 to 0.90), or for morphine usage (*p* = 0.425, 95% CI: −2.88 to 5.58), hypotension (*p* = 0.22, 95% CI: −1.91 to 0.51), rates of failed technique (*p* = 0.488, 95% CI: −2.33 to 1.18), or pulmonary complications (*p* = 0.498, 95% CI: −6.11 to 3.52). However, there was publication bias in urinary retention (*p* = 0.007, 95% CI: −2.59 to −0.77), and nausea and vomiting (*p* = 0.027, 95% CI: −3.5 to −0.32).

Discussion {#s4}
==========

This updated meta-analysis, which included 777 patients, in 18 randomized controlled trials [@pone.0096233-Hotta1]--[@pone.0096233-Kanazi1], [@pone.0096233-Kaiser1]--[@pone.0096233-Bimston1] that compared PVB with EPI for thoracotomy, showed that PVB provides comparable analgesia with epidural blockade and furthermore has a better side effect profile. PVB is associated with less urinary retention, postoperative nausea and vomiting, and hypotension. These results were consistent with those of the meta-analysis performed by R. G. Davies in 2006 [@pone.0096233-Davis1]. However, we also found that there were no significant differences between PVB and EPI in pulmonary complications. We assumed that the direct reason was the different concentration of an infusion of bupivacaine for PVB and EPI in Medha\'s study, the concentration was 0.25% and 0.125% respectively [@pone.0096233-Mohta1], resulted in the incidence of pneumonia was 1 patient (6.7%) in EPI, but 2 patients (13.3%) in PVB group. Bulger et al. [@pone.0096233-Bulger1] also demonstrated that epidural analgesia not only improved outcome for patients with chest wall pain but also decreased risk of nosocomial pneumonia. There was publication bias in urinary retention, nausea and vomiting, we think the reason is that studies with negative results were not published, in other words, positive results are easier to be reported.

Compared to the prior meta-analysis [@pone.0096233-Davis1], approximately half of the articles included in the current study were new, and the quality of these studies was higher than before. Because of these characteristics, we consider this meta-analysis to be much more robust, and the result regarding pulmonary complications differs from the previous study.

Effective postoperative analgesic is believed to reduce morbidity, improve patient outcomes, and reduce hospital costs. Thoracic epidural analgesia is commonly used after thoracotomy. However, there are risks associated with the techniques such as neurological injury and paraplegia [@pone.0096233-Grant1]. Sometimes, the epidural technique fails due to difficult anatomy [@pone.0096233-Arendt1].

Thoracic paravertebral block (PVB) is becoming increasingly popular in recent years. The classic technique described for PVB is a posterior approach using loss of resistance to air or saline as the superior costotransverse ligament is traversed [@pone.0096233-Eason1]. Recent modifications to this technique have utilized ultrasound and nerve stimulation [@pone.0096233-Lang1]. Alternatively, catheters can be placed in the paravertebral space intraoperatively under direct vision by the surgeon before chest closure [@pone.0096233-Sabanathan2]. These methods avoid some of the concerns regarding epidural placement in the presence of difficult anatomy, local sepsis, or impaired coagulation. More importantly, it can reduce the rate of neurological injury and paraplegia.

Many studies have shown thoracic PVB to be an effective form of analgesia after thoracotomy, multiple fractured ribs, major breast surgery, and inguinal hernia repair [@pone.0096233-Karmakar1]. Andreae et al. [@pone.0096233-Andreae1] concluded that Paravertebral block reduced the risk of chronic pain after breast cancer surgery in about one of every 5 women. Schnabel et al. [@pone.0096233-Schnabel1] in 2010 also reported that perioperative PVB is a feasible and effective method for improved postoperative pain after breast surgery. Thavaneswaran et al. [@pone.0096233-Thavaneswaran1] concluded that PVB can be applied during herniorrhaphy. Although our meta-analysis showed that there was no difference in pain scores and pulmonary complications between PVB and EPI, there was a statistically significant improvement in PVB in terms of adverse side effects.

Limitations {#s4a}
-----------

This meta-analysis is characterized by several limitations that should be noted. Firstly, the findings are based on relatively low quality data with a high risk of bias. This is a common limitation of systematic reviews. In addition, only papers written in English were included. Secondly, surgical placement of the catheter under direct vision must influence the results of side effects because it avoids complications and reduces failure rates. Thirdly, various drug regimens were implemented for EPI and PVB. In contrast to the studies of Richardson et al. [@pone.0096233-Richardson1] and Casati et al. [@pone.0096233-Casati1], in which only a local anesthetic solution was used, Tatjana et al. [@pone.0096233-Pintaric1] administrated an infusion of a local anesthetic-opioid combination to both group. This influences not only analgesic efficacy but also respiratory depression, because a combination of local anesthetic and opioid administration carries a high risk of respiratory depression.

Conclusions {#s5}
===========

Our analysis represents a least-biased attempt to pool the results of several studies. A large, prospective, randomized trial is necessary to confirm these findings. Extensive, large, randomized, double-blind, multicenter, controlled clinical trials that compared PVB and EPI will be better.

This meta-analysis showed that PVB can provide comparable pain relief to traditional EPI, and may have a better side-effect profile for pain relief after thoracic surgery. Further high-powered randomized trials are to need to determine whether PVB truly offers any advantages over EPI.

Supporting Information {#s6}
======================
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